Homocysteine in coronavirus disease (COVID-19): a systematic literature review.
Diagnosis (Berl)
; 9(3): 306-310, 2022 08 01.
Article
in English
| MEDLINE | ID: covidwho-1892369
ABSTRACT
OBJECTIVES:
Coronavirus disease 2019 (COVID-19) is a life-threatening infectious disorder characterized by a sustained prothrombotic state. Since homocysteine is a potential biomarker of thrombotic diseases, the aim of this article is to provide an updated overview on the possible role played by hyperhomocysteinemia in influencing an unfavorable COVID-19 progression.METHODS:
We carried out an electronic search in Medline (PubMed interface) using the keywords ("COVID-19" OR "SARS-CoV-2") AND "homocysteine", between 2019 and the present time, with no language restrictions, to identify all articles which explored the concentration of homocysteine in COVID-19 patients with or without unfavorable disease progression.RESULTS:
Three studies, totaling 694 hospitalized COVID-19 patients, were included in our systematic review. Overall, the differences between the mean homocysteine values in non-severe vs. severe COVID-19 patients were always positive (i.e., 15.1%, 24.1% and 22.8%, generating a positive weight mean difference of 1.75 µmol/L (95%CI, 1.26-2.25 µmol/L; p=0.011), which translates into a cumulative difference of approximately â¼1.2 µmol/L.CONCLUSIONS:
Despite the limited evidence that has been garnered so far, increased homocysteine ââlevels may be a potentially useful marker for predicting the risk of unfavorable progression in patients with COVID-19.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Homocysteine
Type of study:
Prognostic study
/
Reviews
/
Systematic review/Meta Analysis
Limits:
Humans
Language:
English
Journal:
Diagnosis (Berl)
Year:
2022
Document Type:
Article
Affiliation country:
Dx-2022-0042
Similar
MEDLINE
...
LILACS
LIS